These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9506002)

  • 1. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol.
    Troy SM; Turner MB; Unruh M; Parker VD; Chiang ST
    J Clin Pharmacol; 1997 Nov; 37(11):1073-81. PubMed ID: 9506002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam.
    Troy SM; Lucki I; Peirgies AA; Parker VD; Klockowski PM; Chiang ST
    J Clin Pharmacol; 1995 Apr; 35(4):410-9. PubMed ID: 7650232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium.
    Troy SM; Parker VD; Hicks DR; Boudino FD; Chiang ST
    J Clin Pharmacol; 1996 Feb; 36(2):175-81. PubMed ID: 8852394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative bioavailability of two formulations of venlafaxine extended-release 75-mg capsules in healthy brazilian male volunteers: A single-dose, randomized-sequence, open-label, two-period crossover study in the fasting and fed states.
    Homero de Souza Filho J; Bonifácio FN; Bedor DC; Ramos VL; de Sousa CE; Sardón LL; Gonçalves TM; Moreira RC; Leal LB; de Santana DP
    Clin Ther; 2010 Nov; 32(12):2088-96. PubMed ID: 21118744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
    Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects.
    Lindauer A; Siepmann T; Oertel R; Jung A; Ziemssen T; Jaehde U; Kirch W; Siepmann M
    Clin Pharmacokinet; 2008; 47(11):721-31. PubMed ID: 18840027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers.
    Modi NB; Dresser M; Desai D; Edgar C; Wesnes K
    J Clin Pharmacol; 2007 Mar; 47(3):315-22. PubMed ID: 17322143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects.
    Patat A; Troy S; Burke J; Trocherie S; Danjou P; Le Coz F; Allain H; Gandon JM
    J Clin Pharmacol; 1998 Mar; 38(3):256-67. PubMed ID: 9549664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participants.
    Setnik B; Sokolowska M; Johnson F; Oldenhof J; Romach M
    Hum Psychopharmacol; 2014 May; 29(3):251-65. PubMed ID: 24911576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
    Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
    Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.
    Bhatara VS; Magnus RD; Paul KL; Preskorn SH
    Ann Pharmacother; 1998 Apr; 32(4):432-6. PubMed ID: 9562139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study.
    Amsterdam JD; Hooper MB; Amchin J
    J Clin Psychiatry; 1998 May; 59(5):236-40. PubMed ID: 9632034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
    Jann MW; Spratlin V; Momary K; Zhang H; Turner D; Penzak SR; Wright A; VanDenBerg C
    Eur J Clin Pharmacol; 2012 May; 68(5):715-21. PubMed ID: 22173281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics.
    Klamerus KJ; Parker VD; Rudolph RL; Derivan AT; Chiang ST
    Pharmacotherapy; 1996; 16(5):915-23. PubMed ID: 8888087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharma-Clinics. The drug of the month. Venlafaxine (Efexor)].
    Ansseau M
    Rev Med Liege; 1998 Feb; 53(2):106-8. PubMed ID: 9564231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine.
    Troy SM; Parker VP; Hicks DR; Pollack GM; Chiang ST
    J Clin Pharmacol; 1997 Oct; 37(10):954-61. PubMed ID: 9505987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine: a heterocyclic antidepressant.
    Ellingrod VL; Perry PJ
    Am J Hosp Pharm; 1994 Dec; 51(24):3033-46. PubMed ID: 7856622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions.
    Unterecker S; Reif A; Hempel S; Proft F; Riederer P; Deckert J; Pfuhlmann B
    Int Clin Psychopharmacol; 2014 Jul; 29(4):206-11. PubMed ID: 24374906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine overdose.
    Coorey AN; Wenck DJ
    Med J Aust; 1998 May; 168(10):523. PubMed ID: 9631679
    [No Abstract]   [Full Text] [Related]  

  • 20. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
    Kennedy SH; McCann SM; Masellis M; McIntyre RS; Raskin J; McKay G; Baker GB
    J Clin Psychiatry; 2002 Mar; 63(3):181-6. PubMed ID: 11926715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.